Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Equity (Tables)

v3.8.0.1
Stockholders' Equity (Tables)
 9 Months Ended
Apr. 30, 2018
Stockholders' Equity Note [Abstract]  
Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Table Text Block] The amounts of share-based compensation expense recognized in the periods presented are as follows:

    Three months ended
April 30,		     Nine months ended
April 30,		  
    2018     2017     2018     2017  
Stock options   $ 202     $ 204     $ 609     $ 586  
Restricted stock     2       5       8       15  
    $ 204     $ 209     $ 617     $ 601  
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block] The following table sets forth the amount of expense related to share-based payment arrangements included in specific line items in the accompanying statements of operations:

    Three months ended
April 30,		     Nine months ended
April 30,		  
    2018     2017     2018     2017  
Cost of clinical laboratory services   $ —     $ 2     $ —     $ 5  
Selling, general and administrative     204       207       617       596  
    $ 204     $ 209     $ 617     $ 601  
Share-based Compensation, Stock Options, Activity [Table Text Block] The following table summarizes stock option activity during the nine month period ended April 30, 2018:

    Options     Weighted
Average
Exercise
Price		     Weighted
Average
Remaining
Contractual
Term		   Aggregate
Intrinsic
Value (000s)		  
Outstanding at July 31, 2017     2,130,995     $ 4.26              
Awarded     117,580     $ 8.36              
Exercised     (615,624 )   $ 2.99         $ 5,896  
Cancelled or expired     (29,334 )   $ 5.94              
Outstanding at end of period     1,603,617     $ 5.02     2.6 years   $ 4,344  
Exercisable at end of period     1,168,489     $ 4.25     1.2 years   $ 2,261  
Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block] A summary of the activity pursuant to the Company’s unvested restricted stock awards for the nine months ended April 30, 2018 is as follows:

    Awards     Weighted
Average
Award Price		  
Outstanding at July 31, 2017     7,436     $ 4.45  
Awarded     —       —  
Vested     (2,562 )   $ (5.51 )
Forfeited     (386 )     (5.62 )
Unvested at end of period     4,488     $ 2.97